Abstract: Recent epidemiological studies and animal experiments have demonstrated that nonsteroidal anti-infl ammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma. Cyclooxygenase (COX)
Introduction
The natural history of the bladder tumor (BT) is not well understood, but exposure to carcinogens, including aromatic amines, is considered a major risk factors for the development of BT. Workers exposed to aromatic amines frequently have a mutated p53 gene, a tumor suppressor gene involved in the tumorigenesis of many tumors.
Non-steroidal anti-infl ammatory drugs (NSAIDs) have anti-tumor effects for the RCC patient, thus, attracting a great deal of attention. The typical target of NSAIDs is cyclooxygenase (COX). In recent reports, a number of patients have had signifi cantly low risks of colorectal cancer while they continued using NSAIDs typifi ed by aspirin. Consequently, the suppression of tumorigenesis by administering NSAIDs has come into focus. It was also reported that the size and number of adenoma were markedly reduced when sulindac, a type of NSAIDs was given to patients with familial adenomatous polyposis, a high risk group for colorectal cancer. 1 It is known that NSAIDs inhibit the activity of COX and production of prostaglandin. NSAIDs also stimulate peroxisome proliferator activator-receptor (PPAR)-γ and inhibit the production of chemical mediators such as tumor necrosis factor-α, interleukin-1β and interleukin-6 through the expression of PPAR-γ in leukocytes. PPAR-γ is thus a promising target for cell growth modulation by NSAIDs.
In this review, we discuss the possibility that the target of arachidonic acid pathway metabolite may be a new anti-tumor strategy for human BT.
Arachidonic Acid Pathway
The metabolism of arachidonic acid by either COX pathway or lipoxygenase (LOX) pathway generates eicosanoids, which have been implicated in the pathogenesis of a variety of human diseases, including cancer, and are considered important in tumor promotion, progression, and metastasis. 2 COX is the fi rst enzyme in the pathway for producing prostaglandin (PG) and thromboxane (Tx) from arachidonic acid, and can occur as three isoforms, COX-1, COX-2 and COX-3. The enzymes of both COX-1 and COX-2 are transformed from the cell membrane phospholipid to arachidonic acid by the phospholipase A 2 , and then transform arachidonic acid to PGH 2 through PGG 2 . COX-1 occurs in tissues and cells and works to protect the cell. COX-2 express momentarily and strongly in response to growth factors and some endotoxins. It is involved with infl ammation, cell proliferation and differentiation. 3 Recently, COX-2 has also been shown to play an important role in tumorigenesis. 1 Although the existence of COX-3 has recently been reported, it continues to be argued. In pathogenesis of BT, Both COX-2 and PGs (especially PGE 2 ) play a role in development of BT.
LOX is the fi rst enzyme in the pathway for producing leukotriene (LT) from arachidonic acid. Isoenzymes of LOX include 5-LOX, 12-LOX and two 15-LOX isoforms (15-LOX-1, 15-LOX-2). These catalyze the biosynthesis of biologically active compounds such as LTs and hydroxyeicosatetraenoic acids (HETEs).
4,5 5-LOX catalyzes the fi rst step in oxygenation of arachidonic acid to produce 5-hydroperoxyeicosatetraenoic acid (5-HPETE), and the subsequent metabolism of 5-HPETE to 5-HETE and LTs. LTs belong to an important group of proinfl ammatory mediators that are synthesized from arachidonic acid via the 5-LOX pathway. The activity of 5-LOX leads to the formation of unstable LTA 4 , which can be converted into either LTB 4 , or cysteinyl LTs (LTC 4 , LTD 4 and LTE 4 ). 6 The 12-LOX, includes platelet 12-LOX, and leukocyte 12-LOX that oxygenate arachidonic acid at position C-12 to produce 12-hydroperoxyeicosatetra-enoic acid and then 12-HETE. 2 Whereas 5-LOX, 12-LOX and 15-LOX-1, have pro-tumorigenic roles, 15-LOX-2 appears to have an anti-tumorigenic roles. The administration of LOX inhibitor may inhibit matrix metalloproteinase (MMP)-2, it may induce down regulation such as BCL-2 and nuclear factorkappaB (NF-λB), and it may activate such as PPAR-γ, apoptosis activating factor-1 and caspase-3.
PPAR
PPARs are members of the nuclear receptor super-family of ligand-activated transcriptional factor such as steroids, thyroid hormone, vitamin D 3 and retinoic acid. 7 PPAR binds to peroxisome proliferator response element (PPRE) as a heterodimer with the retinoic receptor (RXR) in the regulation of PPAR target genes. PPARs may be important immunomodulatory factors as well as fatty acid regulators. PPARs modulate these activities in different immune cell types such as monocyte/macrophages, lymphocytes, and endothelial cells.
Three PPAR subtypes (α, β, and-γ) have been identifi ed. PPAR-α is highly expressed in the liver, heart, kidney, muscle, brown adipose tissue, and gut tissues which exhibit high carbolic rates towards fatty acid. 8 PPAR-β is expressed ubiquitously, and its function is relatively unknown. 9 Recent studies suggest that PPAR-β may be a target for NSAID-induced tumor suppression in colorectal tumors. PPAR-γ is expressed at highlevel in adipose tissue and is a critical regular of adipocyte differentiation. In addition, PPAR-α, and -γ may be important immunomodulatory factors. PPAR-α-knockout mice exhibit exacerbated infl ammatory responses, and LTB 4 , a chemotactic mediator, seems to regulate the clearance of itself as an agonist of PPAR-α. PPAR-γ is also expressed in the immune system tissues and cells (spleen, bone-marrow, monocytes, helper T-cell clones) and skeletal tissues (bone, synovioum, chondrocytes).
8 PPAR-γ also have an anti-tumorigenic roles.
Recent data have shown that PPAR-γ ligands lead to inhibition of phorbol ester-induced nitric oxide and macrophage-derived cytokines. PPAR-γ ligands also induce apoptosis in macrophage, fi broblasts, and endothelial cells. 10 PPAR-γ plays a role in both adipocyte differentiation and tumorigenesis. PPAR-γ ligands lead to inhibition of the expression of nitric oxide, cytokines, chemokines and adhesion molecules, in part by antagonizing the activities of transcriptional factors. Furthermore, PPAR-γ ligands including anti-diabetic thiazolidinedione (such as troglitazone) and 15-deoxy-∆ 12,14 -prostaglandin J 2 (15-d-PGJ 2 ) have potent tumor modulatory effects on several tumors. 11, 12 15-d-PGJ 2 induces apoptosis in macropharge, endothelial cell, and choriocarcinoma cell [13] [14] [15] as well as thiazolidinediones-induced fibroblast apoptosis. 16 PPAR-γ ligands also inhibit vascular endothelial cell growth factor-induced angiogenesis in vivo. 17 Angiogenesis is important for carcinogenesis. Anti-angiogenetic therapy is highly promising since it does not induce aquired anticancer drug resistance. 18, 19 Drevs et al. demonstrated the effect of PTK787/ZK 222584, a specifi c inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood fl ow in an animal model of renal cell carcinoma. 20 PPAR-γ agonists induce apoptosis in endothelial cells and inhibit vascular endothelial growth factor-induced angiogenesis in rats. Therefore, PPAR-γ ligands may have anticancer-effects through inhibition of cell proliferation and angiogenesis.
COX and BT
COX-2 expression in BT tissues was stronger than in chronic cystitis (CC) and normal bladder (NB) tissues by immunohistochemical staining (118 BT, 10 CC and 8 NB tissues) or RT-PCR (Fig. 1) . We classifi ed 3 categories (epithelium, blood vessel, stromal tissue) in BT tissues, and examined them for intensity of COX-2 expression. COX-2 expression was more intensive and extensive in all categories of BT tissues than CC and NB tissues. Signifi cant differences occurred between grades of BT tissues in only epithelium in COX-2 expression. COX-2 expression was stronger in G3 cancer and advancedstage BT (pT2 or above). 21 Mohammed et al. reported the expression of COX-1 in both BT and NB tissues by immunohistochemical staining and western blot. COX-2 was stronger in the advanced stage BT than NB tissue. 22 Komhoff et al. reported COX-2 expression was stronger in low differentiation BT by immunohistochemical staining. 23 Shirahara et al. reported COX-2 expression was stronger in the advanced-stage BT, and COX-2 expression was most strongest in the highest malignancy of BT in situ, and COX-1 expression was nothing in any BT tissues by immunoblot and immunohistochemical staining. 24 Margulis et al. reported COX-2 was not expressed in NB urothelium. COX-2 over expression is associated with pathological and molecular features of biologically aggressive disease, suggesting a role for COX-2 in BT development and invasion. 25 Okajima et al. reported the administration of nimesulide and piroxicam as selective COX-2 inhibitor could reduce remarkable lowering of tumorigenesis rate in the BT using rat model which superficial BT initiating the tumor by administering the N-butyl-N-nitrosoamine. 26 Okamoto et al. reported etodolac (selective COX-2 inhibitor) exhibited anti-tumor activity and induced E-cadherin expression in BT cells and might be useful for the clinical treatment and prevention of BT, especially in poorly differentiated bladder cancer with high COX-2 and low E-cadherin expression. 27 However, recently accepted explanation is that only celecoxib, among the COX-2 inhibitors induces apoptosis of cancer cells. We suggest the increased apoptosis cells produced by celecoxib might be associated with decreased PGE 2 production.
Generally, Bcl-2 is a key factor suppressing the apoptosis accompanying of caspase. Gee et al. reported treatment with 100 μM celecoxib resulted in signifi cant apoptosis in three kinds of BT cell lines, which was associated with down-regulation of Bcl-2. 28 In our experiment, we could not demonstrate signifi cant apoptosis induction by administering eight kinds of COX-2 inhibitors (10-80 μM) into the human BT cell lines (T24) ( Table 1) . Additionally, we could not demonstrate the signifi cance of both selective COX-2 inhibitor (etodolac, meloxicam, nimesulide and NS398) and relatively poor selective COX-2 inhibitor (ibuprofen, indomethacin, piroxicam and s-naparoxen). 29 In conclusion, COX-2 expression is strong in BT, but the anti-tumor effect of COX-2 inhibitor is very weak in BT patients in a single administration at a clinical dose. It may be diffi cult to The dose-response analysis of viability in human BT cell line (T24) treated with COX-2 and LOX inhibitors, and PPAR-γ ligand (5-80 μM, 48 hr) was measured by the MTT assay and expressed as % of control culture conditions. suppress the growth of BT for chemotherapy. COX-2 inhibitor is suitable for chemopreventive therapy.
LOX and BT
We have shown that 5-and 12-LOX expressions in BT tissues were stronger than those in NB tissues by immunohistochemical staining (170 BT, 20 CC and 20 NB tissues) (Fig. 2) and RT-PCR. We classifi ed 3 categories (epithelium, blood vessel, stromal tissue) in BT, CB and NB tissues, and examined the intensity of 5-and 12-LOX expressions. 5-and 12-LOX expressions were more intensive and extensive in all categories of BT tissues as compared with CC and NB tissues (Table 2) . 5-LOX expression was stronger in G3 cancer and advanced-stage BT (pT2 or above) than G1 cancer and early-stage BT (pT1 or below).
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At 10-80 μM, some, but not all LOX inhibitors reduced the viability of BT cell lines (T24) by MTT assay (Table 1) potent than the 12-LOX inhibitor. 30 BT cells treated with some LOX inhibitor (50 μM) showed chromatin condensation, cellular shrinkage, apoptotic bodies, and cytoplasmic condensation by hoechest staining (Fig. 3) .
BT cells treated with 5-LOX inhibitor (100 μM) also entered early apoptosis, but not late apoptosis, necrosis or DNA fragmentation by fl ow cytometry.
Hayashi et al. reported BT cells frequently expressed 5-LOX. 5-LOX inhibitor (AA861) revealed the strongest growth suppression of those cells compared to other LOX and COX pathway inhibitors, and the growth suppression effects were considered to be due to inhibition of the enzymatic activity. 31 In conclusion, 5-LOX expression is strong in BT, especially low differentiation and advancedstage BT. The anti-tumor effect of 5-LOX inhibitor is signifi cantly stronger than those of COX-2 inhibitor. The anti-tumor effect of 5-LOX inhibitor is weak in BT patients in a single administration at a clinical dose. 5-LOX inhibitor is suitable for chemopreventative therapy, like COX-2 inhibitor.
PPAR-γ and BT
By immunohistochemical staining and RT-PCR, PPAR-γ expression is increased in BT tissues as compared with NB tissues (170 BT and 20 NB tissues). In all categories (epithelium, blood vessel, stromal tissues) of BT and NB tissues, the intensity of PPAR-α, -β expression was not signifi cantly different. In all categories, PPAR-γ expression was signifi cantly greater in BT tissues than in NB tissues. Only epithelium, PPAR-γ expression was stronger in G3 cancer. In all categories, PPAR-γ expression was stronger in advanced-stage BT (pT2 or above). (T24) by MTT assay (Table 1) . BT cells treated with PPAR-γ ligands (25 μM troglitazone and 15-d-PGJ 2 ) could early apoptosis, not late apoptosis or necrosis and DNA fragmentation by fl ow cytometry (Fig. 4) . PPAR-γ ligands (20 μM troglitazone and 15-d-PGJ 2 ) also induced apoptosis in BT cells by hoechest staining. In conclusion, PPAR-γ is strong in BT, and the anti-tumor effect of PPAR-γ ligand is signifi cantly greater than that of 5-LOX inhibitor. The antitumor effect of PPAR-γ ligand is relatively weak. Targeting PPAR-γ in BT is likely to be useful more as a chemopreventive rather than chemotherapeutic.
Conclusions
There is no discussion that COX-2, LOX (especially, 5-LOX) and PPAR-γ are involved in the initiation and promotion of BT tissues. It may be possible to use COX-2 and 5-LOX inhibitor, and PPAR-γ ligand as an anti-tumor drug for chemopreventive therapy in a single administration at a clinical dose. However, it may be diffi cult to use the COX-2 and 5-LOX inhibitor, even if PPAR-γ ligand in single administration at a clinical dose in expectation for chemotherapeutic therapy. However, the clinical application of PPAR-γ ligand and 5-LOX inhibitor require further research and consideration, the target of PPAR-γ ligand and 5-LOX inhibitor is a novel strategy over human BT. We conclude the administration of COX-2 and 5-LOX inhibitor, and PPAR-γ ligand are useful with usual treatment in human BT. In near future, the combination therapy of COX-2 and 5-LOX inhibitor, and PPAR-γ ligand will be useful new treatment of human BT.
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